M.D. Anderson Cancer Center
This is an open-label, single institution, Phase 1 study of Venetoclax, Dexamethasone, Bortezomib, and Daratumumab for adolescent and young adult participants with relapsed or refractory T-ALL or T-LBL
Primary Objective: • To determine the safety and tolerability of the combination of Venetoclax, Dexamethasone, Bortezomib, and Daratumumab for adolescent and young adult patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or Lymphoma (LBL). Secondary Objectives: * To conduct a preliminary assessment of efficacy in adolescent and young adult patients treated with this combination based on: * Best overall response (BOR), including complete remission (CR), CR with partial hematological recovery (CRh), CR with incomplete blood count recovery (Cri), morphologic free…
Inclusion Criteria: * Weight must be \> or = to 40 kg * Patients must have histologically or cytologically confirmed relapsed or refractory T-ALL or TLBL. * Age ≥ 12 year to ≤ 30 years. * Lansky ≥60 for patients \<16, Karnofsky ≥60 for patients ≥ 16 years of age. (See Appendix I) * Baseline ejection fraction must be \> 40% OR Shortening fraction \>20%. Either can be used at the investigator's discretion. * Adequate hepatic function (direct bilirubin \< 1.5x upper limit of normal (ULN) unless increase is due to Gilbert's disease or leukemic involvement, and AST and/or ALT \< 5x ULN unless cons…
Given by mouth
Given by mouth or IV
Given subcutaneously or IV
Given by IV
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.